Eli Lilly reported Q1 2026 results on April 30 ↗ with revenue of $19.8 billion, up 56% year over year, and raised full-year 2026 revenue guidance by $2 billion at each end of the range to $82-85 billion. The print confirms the framing the news section laid out on April 27 as the swing earnings date for the obesity-drug cycle. Mounjaro ↗ and Zepbound ↗ carried the quarter; Foundayo, the oral semaglutide ↗-class candidate that anchored that pre-earnings setup, did not.
The numbers worth holding. Mounjaro hit $8.66 billion globally in the quarter, up 125% year over year. Zepbound delivered $4.16 billion in U.S. sales, up 80%. Together, the two GLP-1/GIP dual-agonist products produced $12.8 billion in a single quarter, which would by itself be a top-twenty pharmaceutical revenue stream on an annualized basis. Reported Q1 EPS was $8.26, up 170%. The 56% top-line growth was 65% volume growth offset by a 13% price decline, which is the cleanest single number for the demand-versus-pricing-pressure question that has dominated GLP-1 commentary over the past year. Volume is up. Price is down. Volume is up substantially more than price is down, so Lilly's net is up.
The guidance raise is the more significant signal. A $2-billion raise at each end of the range, to $82-85 billion, implies management believes the back half of the year will exceed the prior plan by a meaningful margin. The non-GAAP EPS guidance now sits at $35.50-$37.00, also raised. The five positive Phase 3 readouts the release recapped, plus six new Phase 3 starts in the quarter, plus the closings of the Orna Therapeutics, Centessa, Colonia, and Ajax acquisitions, position the company for pipeline diversification beyond the GLP-1 core. The Kelonia in vivo CAR-T deal announced April 20 is the most visible of those moves; the section will track that pipeline pivot over the coming quarters.
What did not show up in the headline. Foundayo, the oral semaglutide-class product that the news section flagged on April 27 as the swing element of the cycle, was not the lead Q1 narrative. The release framed the quarter around Mounjaro and Zepbound, with Foundayo absorbed into broader product commentary. The implication is that Foundayo's launch trajectory has not changed Lilly's strategic reading of the cycle, but it also has not produced the upside the Hims & Hers commentary in late April had implied. The product is launching into a market dominated by injectable GLP-1s and a regulatory environment that just (per the same April 30 news cycle) tightened around compounded alternatives. Both forces help Foundayo over time. Neither helps it in Q1.
The competitive read. Novo Nordisk reports Q1 on May 6, six days from this print. Lilly's beat sets a high bar. The market expects similar volume strength on the Wegovy ↗-Ozempic ↗ side, with the additional question of how Novo characterizes CagriSema's Phase 3 progression and the upcoming ECO 2026 data presentations in late May. The petrelintide ↗ Phase 3 endorsement from Roche/Zealand on April 29, the FDA 503B compounding proposal on April 30, and Novo's own Q1 print on May 6 collectively define the second wave of obesity-drug competitive structure for 2026 and beyond.
The platform read. Mounjaro and Zepbound are formulations of tirzepatide ↗, the GLP-1/GIP dual agonist that anchored Lilly's commercial dominance through 2025. The platform's GLP-1R ↗ and GIPR ↗ target pages remain the most clinically relevant in the metabolic-disease corner of the corpus. The Q1 numbers ratify the design choice that drove the field for the past three years: dual-agonist beats single-target on weight loss, and the resulting market is large enough that the early-mover commercial position is defensible.
What the rest of 2026 has to prove. The unresolved questions: whether Foundayo accelerates as it scales, whether Novo's Q1 plus ECO data plus CagriSema Phase 3 progression can match Lilly's Q1 trajectory, and whether the 503B compounding closure converts to actual price firmness on the branded products. Each is testable within the year. The case for continuing GLP-1 pricing power, weakened in late 2024 by compounding competition and federal-coverage debates, looks stronger today than at any point in the past nine months.